End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
118,500 KRW | +0.42% | +5.90% | -5.58% |
05-20 | Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval | CI |
05-16 | GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on GC Biopharma Corp.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.38% | 2 M€ | -14.14% | ||
0.05% | 2 M€ | -.--% | ||
0.01% | 4 M€ | -4.41% | - | |
0.01% | 7 M€ | +6.43% | - | |
0.00% | 112 M€ | +4.86% | - | |
0.00% | 34 M€ | +9.03% | - | |
0.00% | 306 M€ | +6.45% | - | |
0.00% | 39 M€ | +6.61% | - | |
0.00% | 34 M€ | +4.23% | - |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.58% | 986M | |
+43.64% | 749B | |
+39.42% | 605B | |
-6.58% | 351B | |
+19.72% | 328B | |
+8.78% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.03% | 167B | |
+6.13% | 165B |
- Stock Market
- Equities
- A006280 Stock
- Funds and ETFs GC Biopharma Corp.